Efficacy and safety of selective JAK 1 inhibitor Filgotinib in active rheumatoid arthritis patients with inadequate response to conventional synthetic disease-modifying antirheumatic drugs: Comparative study with Filgotinib and interleukin 6 inhibitor examined by clinical index as well as musculoskeletal ultrasound assessment(TRANSFORM study): Study protocol for a randomized, open-label, parallel-group, multicenter, and non-inferiority clinical trial

Start Date25 May 2021

Sponsor / Collaborator-

100 Clinical Results associated with Interleukin-6(Ajinomoto Co., Inc.)

100 Translational Medicine associated with Interleukin-6(Ajinomoto Co., Inc.)

100 Patents (Medical) associated with Interleukin-6(Ajinomoto Co., Inc.)

Literatures (Medical) associated with Interleukin-6(Ajinomoto Co., Inc.)

01 Aug 2024·Journal of the American College of Cardiology

Effect of Time-Varying Exposure to School-Based Health Promotion on Adiposity in Childhood

Article

Author: Santos-Beneit, Gloria ; Haro, Domingo ; Fernández-Alvira, Juan Miguel ; Carvajal, Isabel ; Peyra, Carlos ; Carral, Vanesa ; Martínez-Gómez, Jesús ; de Cos-Gandoy, Amaya ; Rodríguez, Carla ; Fuster, Valentin ; Fernández-Jiménez, Rodrigo ; de Miguel, Mercedes ; Bodega, Patricia ; Orrit, Xavier

BACKGROUNDThe results of most school-based health promotion initiatives are inconclusive.OBJECTIVESThis trial assessed the effect of time-varying exposures to a multicomponent school-based health promotion intervention (SI! Program) on adiposity markers.METHODSA total of 48 schools in Madrid (Spain) were cluster randomized to receive the SI! Program through elementary education grades 1 to 6 (E1-6, 12 schools, 459 children), 1 to 3 (E1-3, 12 schools, 513 children), or 4 to 6 (E4-6, 12 schools, 419 children) or to receive the standard curriculum (control, 12 schools, 379 children). The primary endpoint was the between-group difference at 3- and 6-year follow-up in the change from baseline in adiposity markers and the overall knowledge-attitudes-habits (KAH) score.RESULTSAt 3-year follow-up, children who had the intervention showed significantly lower increases than the control group in z-scores for body mass index (BMI), waist-to-height ratio (WHtR), and waist circumference (WC) (zBMI: -0.09; 95% CI: -0.16 to -0.03; P = 0.003; zWC and zWHtR: -0.19; 95% CI: -0.28 to -0.10; P < 0.001). At 6-year follow-up, the beneficial trend in zWC and zWHtR was maintained in the E1-6 and E1-3 groups: difference zWC control vs E1-6 (-0.19; 95% CI: -0.36 to -0.03; P = 0.020), control vs E1-3 (-0.22; 95% CI: -0.38 to -0.06; P = 0.009); difference zWHtR control vs E1-6 (-0.24; 95% CI: -0.41 to -0.06; P = 0.009), and control vs E1-3 (-0.29; 95% CI: -0.47 to -0.11; P = 0.001). No significant between-group differences were found in the change of overall KAH score.CONCLUSIONSEarly elementary school interventions may be more effective than later interventions on abdominal adiposity. Further research should assess the sustainability effects of school-based health promotion programs.

01 Dec 1990·KardiologiiaQ4 · MEDICINE

[Indications for using a method of pulsed therapy with cyclophosphamide and 6-methylprednisolone in patients with nonspecific aortoarteritis in the acute and subacute stages].

Q4 · MEDICINE

Article

Author: Iudin, V I ; Zotikov, A E ; Pokrovskiĭ, A V ; Varava, B N

01 Jan 1988·RespirationQ3 · MEDICINE

Muscle Atrophy in Severe Exacerbation of Asthma Requiring Mechanical Ventilation

Q3 · MEDICINE

Article

Author: Picado, C ; Montserrat, J ; Agusti-Vidal, A

An unusual case of acute muscular atrophy in a patient with a severe exacerbation of asthma requiring mechanical ventilation is reported. High doses of pancuronium bromide and 6-methylprednisolone were administered. It is suggested that the conditions of mechanical ventilation increase in some way the potential of corticosteroids to cause myopathy. The possible implication of myorelaxant drugs in the development of this complication is also suggested.

100 Deals associated with Interleukin-6(Ajinomoto Co., Inc.)

External Link

KEGG	Wiki	ATC	Drug Bank
-	Interleukin-6(Ajinomoto Co., Inc.)	-	-

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Thrombocytopenia	Phase 2	-	Ajinomoto Co., Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Interleukin-6(Ajinomoto Co., Inc.)

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation